Chengfu Xu

6.8k total citations · 1 hit paper
183 papers, 4.9k citations indexed

About

Chengfu Xu is a scholar working on Epidemiology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Chengfu Xu has authored 183 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Epidemiology, 48 papers in Surgery and 32 papers in Pathology and Forensic Medicine. Recurrent topics in Chengfu Xu's work include Liver Disease Diagnosis and Treatment (91 papers), Diet, Metabolism, and Disease (26 papers) and Alcohol Consumption and Health Effects (26 papers). Chengfu Xu is often cited by papers focused on Liver Disease Diagnosis and Treatment (91 papers), Diet, Metabolism, and Disease (26 papers) and Alcohol Consumption and Health Effects (26 papers). Chengfu Xu collaborates with scholars based in China, United States and France. Chengfu Xu's co-authors include Chaohui Yu, Youming Li, Lei Xu, Min Miao, Youming Li, Xingyong Wan, Hangkai Huang, Han Ma, Shenghui Chen and Yiming Lin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Chengfu Xu

169 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study

2022 139 citations Jiarong Xie, Hangkai Huang et al. profile →

Peers

Countries citing papers authored by Chengfu Xu

Since Specialization

Citations

This map shows the geographic impact of Chengfu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengfu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengfu Xu more than expected).

Fields of papers citing papers by Chengfu Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengfu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengfu Xu. The network helps show where Chengfu Xu may publish in the future.

Co-authorship network of co-authors of Chengfu Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Chengfu Xu. A scholar is included among the top collaborators of Chengfu Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengfu Xu. Chengfu Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nanozyme engineered ROS-tolerant cysteine active-site for upstream deubiquitylation therapy of inflammatory bowel disease 2025 ·Nano Today ·(unknown), (unknown), (unknown), (unknown), Ziyan Huang, (unknown), (unknown), Keli Yang, Yuting Xie, Chengfu Xu, (unknown), (unknown), Lingfeng Chen, (unknown), (unknown), Daishun Ling, Guang Liang	0
2	Remnant cholesterol predicts the development of type 2 diabetes in patients with nonalcoholic fatty liver disease 2025 ·Diabetology & Metabolic Syndrome ·(unknown), Hangkai Huang, Zejun Wang, Chengfu Xu	1
3	TJ0113 attenuates fibrosis in metabolic dysfunction-associated steatohepatitis by inducing mitophagy 2025 ·International Immunopharmacology ·(unknown), (unknown), Xufeng Cen, Ting Ye, Hui Qu, Si‐Jia Chen, Dong Liu, Hongguang Xia, Chengfu Xu, Jiansheng Zhu	2
4	Macrophages and pulmonary fibrosis: a bibliometric and visual analysis of publications from 1990 to 2023 2024 ·Frontiers in Medicine ·Min Yi, Lifei Wu, Chengfu Xu, (unknown), (unknown), Pan Xu, Luyao Sun, Jinrong Zhang, Guoqiang Wan, (unknown)	2
5	Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank 2024 ·Nature Communications ·Zhening Liu, Hangkai Huang, Jiarong Xie, Yingying Xu, Chengfu Xu	11
6	Relationship between skeletal muscle mass loss and metabolic dysfunction-associated fatty liver disease among Chinese patients with metabolic dysregulation 2024 ·Revista da Associação Médica Brasileira ·Miao Xu, (unknown), Naibin Yang, Jialin Li, Li Li, (unknown), Chengfu Xu	1
7	Global burden trends of MAFLD‐related liver cancer from 1990 to 2019 2023 ·Hangkai Huang, (unknown), Miao Xu, Yishu Chen, Chengfu Xu	3
8	NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis 2023 ·Journal of Psychiatric Research ·Hangkai Huang, Zhening Liu, Jiarong Xie, Chengfu Xu	12
9	The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene–diet study from the UK Biobank 2023 ·American Journal of Clinical Nutrition ·Zhening Liu, Hangkai Huang, (unknown), Zejun Wang, Chengfu Xu	6
10	Circulating fatty acids, genetic risk, and incident coronary artery disease: A prospective, longitudinal cohort study 2023 ·Science Advances ·(unknown), Xiaohui Liu, Yin Li, Yuqi Wu, (unknown), Xuzhi Wan, (unknown), Chengfu Xu, Jingjing Jiao, Yu Zhang	15
11	Dietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants 2023 ·Nutrients ·(unknown), Hangkai Huang, Jiarong Xie, Chengfu Xu	3
12	Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial 2023 ·The American Journal of Gastroenterology ·(unknown), Jinghua Wang, (unknown), (unknown), (unknown), Yanjiao Wang, Ziwei Wang, Jianguo Gao, Chengfu Xu, Han Ma, (unknown), Lan Li, Yi Chen	22
13	Associations of serum uric acid levels with liver disease‐related morbidity and mortality: A prospective cohort study of the UK Biobank 2023 ·Liver International ·(unknown), Hangkai Huang, Jiarong Xie, Chengfu Xu	4
14	Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011–2018 2022 ·British Journal Of Nutrition ·(unknown), Hangkai Huang, Yan Zeng, Yishu Chen, Chengfu Xu	19
15	Associations of Hemoglobin Adducts of Acrylamide and Glycidamide with Prevalent Metabolic Syndrome in a Nationwide Population-Based Study 2022 ·Journal of Agricultural and Food Chemistry ·Xuzhi Wan, Fanghuan Zhu, Pan Zhuang, Xiaohui Liu, (unknown), Wei Jia, Jingjing Jiao, Chengfu Xu, Yu Zhang	9
16	Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease 2022 ·Canadian Journal of Gastroenterology and Hepatology ·(unknown), (unknown), Cen Li, Jinghua Wang, Juanwen Zhang, (unknown), Chengfu Xu	6
17	Association between Monocyte to High‐Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross‐Sectional Study 2021 ·Mediators of Inflammation ·Hangkai Huang, (unknown), Xiaoying Shi, Yishu Chen, Chao Shen, Juanwen Zhang, Chengfu Xu	25
18	Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study 2021 ·Environmental Health ·Zhening Liu, Jinghua Wang, Shenghui Chen, Chengfu Xu, Yu Zhang	10
19	Serum Sialic Acid Level Is Significantly Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: A Cross-Sectional Study 2016 ·BioMed Research International ·(unknown), Han Ma, Chengfu Xu, (unknown), (unknown), Youming Li	13
20	Clinical features and prognostic factors of chronic glomerulonephritis with malignant hypertension 2004 ·Chengfu Xu	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact